ArticleBMC cancer2025
Association of phenotypic age acceleration with all-cause and cause-specific mortality among U.S. cancer survivors: a retrospective cohort study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Article
- Phenotypic age metrics for risk stratification of chronic disease burden and all-cause mortality in adults.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Article
- Association of the waist-to-weight index with low back pain: a mediation analysis involving accelerated biological ageing.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Association Between Estimated Glucose Disposal Rate and Biological Aging Among U.S. Adults: A Cross-Sectional Study.Health science reports · 2026Article
- Phenotypic age acceleration and all-cause and cardiovascular mortality among U.S. adults at risk for heart failure.American heart journal plus : cardiology research and practice · 2026Article
- Biological aging enhances prognostic stratification beyond chronological age in breast cancer brain metastases.Journal of neuro-oncology · 2026Article
- Article
- Article
- The association between a newly proposed gut microbiota dietary index and obesity among U.S. adults: a cross-sectional analysis based on NHANES 1999-2020.Nutrition journal · 2025Article
- GrimAge and GrimAge2 Age Acceleration effectively predict mortality risk: a retrospective cohort study.Epigenetics · 2025Article
- Association of biological age acceleration with mortality in adults with diabetes or prediabetes: a mediating role of physical activity.Aging clinical and experimental research · 2025Article
- AI-driven chemotoxicity prediction in colorectal cancer: impact of race, SDOH, and biological aging.BMC cancer · 2025Article
- Biological Aging and Chemotoxicity in Patients with Colorectal Cancer: A Secondary Data Analysis Using EHR Data.Current oncology (Toronto, Ont.) · 2025Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCancer survivors may experience accelerated biological aging, increasing their risk of mortality. However, the association between phenotypic age acceleration (PAA) and mortality among cancer survivors remains unclear. This study aimed to evaluate the relationship between PAA and all-cause mortality, cancer-specific mortality, and non-cancer mortality among adult cancer survivors in the United States.
methodsWe utilized data from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2018, including 2,643 (unweighted) cancer patients aged ≥ 20 years. Phenotypic age was calculated using ten physiological biomarkers, and the residuals from regressing phenotypic age on chronological age (age acceleration residuals, AAR) were used to determine PAA status. Participants were divided into PAA and without PAA groups based on the sign of the residuals. Weighted Cox proportional hazards regression models were used to assess the association between PAA and mortality, adjusting for demographic characteristics, lifestyle factors, and comorbidities. Restricted cubic spline (RCS) models were employed to explore the dose-response relationship between AAR and mortality.
resultsOver a median follow-up of 9.16 years, 991 (unweighted) participants died. After adjusting for multiple covariates, PAA was significantly associated with increased risks of all-cause mortality (HR = 2.07; 95% CI: 1.69-2.54), cancer-specific mortality (HR = 2.15; 95% CI: 1.52-3.04), and non-cancer mortality (HR = 2.06; 95% CI: 1.66-2.57). Each one-unit increase in AAR was associated with a 4% increase in the risk of all-cause, cancer-specific, and non-cancer mortality (HR = 1.04; 95% CI: 1.03-1.05). RCS models indicated a linear dose-response relationship between AAR and mortality.
conclusionsAmong U.S. adult cancer survivors, PAA is significantly associated with all-cause, cancer-specific, and non-cancer mortality. PAA may serve as an important biomarker for predicting prognosis in cancer survivors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.